Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947917 · ClinicalTrials.gov registry record · NA
Axillary Lymph Node Tattoo Marking Study
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT04947917: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT04947917 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04947917, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study investigates if SpotTM ink can help breast surgeons retrieve sampled lymph node as well as or better than the standard clip and radioseed guidance methods. The names of the novel study intervention involved in this study is: * SpotTM ink tattooing The names of the standard of care study interventions involved in this study are: * Core needle biopsy and/or fine needle aspiration * Surgical Removal of the Lymph Nodes via clip and radioseed guidance
Primary Outcome
The primary endpoint is feasibility. Feasibility will be defined by the successful intra-operative rate of retrieval of the lymph nodes tagged by SpotTM ink versus the clip and radioseed.
Interventions
- PROCEDURE SpotTM Tattoo Ink
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2023-04-13 |
| Phase | NA |
Why NCT04947917 stopped before completion
NCT04947917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which SpotTM Tattoo Ink is the first listed.
NCT04947917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04947917 about?
NCT04947917 is a clinical study titled "Axillary Lymph Node Tattoo Marking Study". This research study investigates if SpotTM ink can help breast surgeons retrieve sampled lymph node as well as or better than the standard clip and radioseed guidance methods. The names of the novel study intervention involved in this study is: * SpotTM ink tattooing The names of the standard of ...
What is the current status of trial NCT04947917?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2021-12-29. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT04947917?
The interventions under investigation include: SpotTM Tattoo Ink (PROCEDURE).
Who is sponsoring clinical trial NCT04947917?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04947917's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI